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     BSTRACT
A fifteen-year-old, male, castrated American Staffordshire terrier was presented with a 
subcutaneous, ulcerated mass on the right carpal joint. Thoracic radiographs and abdominal 
ultrasound were both negative for metastatic disease. Punch biopsies revealed the histopatho-
logical diagnosis of a malignant peripheral nerve sheath tumor. Due to the extent of the primary 
mass, local excision was not possible, and amputation of the limb was not an option for the 
owner. The dog was treated with intravenous administration of combretastatin A4-phosphate, 
a vascular disrupting agent. A biopsy was taken before and after treatment and power-Doppler 
ultrasound and contrast-enhanced ultrasound were performed to assess pre- and posttreatment 
evaluation of the tumor vasculature. The treatment resulted in massive necrosis of the tumor. 
SAMENVATTING
Een vijftienjarige, mannelijke, gecastreerde Amerikaanse staffordshireterriër werd aangeboden 
met een subcutane, ulceratieve massa ter hoogte van het rechter carpaal gewricht. Thoraxradio-
grafieën en een abdominale echografie waren beide negatief voor metastasen. Er werden punchbiopten 
genomen van de massa waaruit histopathologisch een maligne perifere zenuwschedetumor werd ge- 
diagnosticeerd. Doordat de primaire massa zo uitgebreid was, was chirurgische excisie onmogelijk en 
amputatie van de voorpoot was geen optie voor de eigenaar. De hond werd intraveneus behandeld met 
combretastatin A4-phosphate, een stof die het cytoskelet van immature bloedvaten verstoord. Voor en 
na de behandeling werd een biopt genomen en via “power-doppler ultrasound” en contrastechografie  
werd de doorbloeding van de tumor voor en na de therapie opgevolgd. De behandeling resulteerde in 
massale necrose van de tumor. 
A
  Case report 
INTRODUCTION
Cancer is an important cause of death in compan-
ion animals (Farese et al., 2012). Pets with cancer 
often have very advanced (locally invasive and/or 
metastatic) disease when presented to a veterinarian 
(Farese et al., 2012). 
Soft tissue sarcomas, such as peripheral nerve 
sheath tumors (PNST), are a heterogenous population 
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of mesenchymal tumors that comprise around 15% 
and 7% of all skin and subcutaneous tumors in dogs 
and cats, respectively (Liptak and Forrest, 2013). Most 
dogs that are presented with a soft tissue sarcoma are 
between three and twelve years old (Targett et al., 
1993). There is no specific breed or sex predilection 
for soft tissue sarcomas (Liptak and Forrest, 2013). 
PNSTs are most commonly located on the extremities 
(Brehm et al., 1995). In the early stage of the disease, 
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clinical presentation of a PNST is indistinguishable 
from other causes of lameness (da Costa et al., 2008). 
Treatment consists of surgical excision, amputation of 
the affected limb, radiation or, sometimes, palliative 
administration of corticosteroids (Targett et al., 1993; 
Saunders et al., 1998). 
Whenever surgery is not an option, other therapies 
might have potential. Apart from chemotherapy and 
radiation, the use of drugs such as vascular disruptive 
agents (VDA) might be explored. Treatment with a 
VDA is not yet approved by the US Food and Drug 
Administration (FDA) in companion animals, but re-
cent (pre)clinical studies in dogs have demonstrated 
positive results (Abma et al., 2017; Abma et al., 2018). 
Combretastatin A4-phosphate (CA4P) is a vas-
cular disrupting agent that is originally derived from 
the tree called “Combretum caffrum”, a South Afri-
can willow. It is a tubulin-binding agent that desta-
bilizes the microtubules and disrupts the endothelial 
cells of the immature tumoral vasculature (Young and 
Chaplin, 2004), leading to endothelial cell death and 
resulting in ischemia and necrosis of the tumor cells 
(Kanthou et al., 2004). CA4P is an effective antivas-
cular agent that interferes with regrowth of blood ves-
sels by activating cell death pathways (Kanthou et al., 
2004). Vascular disrupting agents such as CA4P are 
very specific and also selective in their target for vas-
cularization because they only focus on the immature 
vessels. Immature vasculature present in the central 
part of the tumor is sensitive, whereas vessels of the 
periphery and surrounding normal tissues are mature 
and therefore will not be destroyed (Siemann et al., 
2005). Despite its selectivity, there is proof that CA4P 
Figure 1 A. Caudal view of the ulcerative and solid tumoral mass at the level of the right carpal joint of a 15-year-old 
American Staffordshire terrier. B. Macroscopic view of the tumor three weeks after treatment. The mass decreased in 
size and the overlying skin had a less irritated and less ulcerative aspect. Regions where the biopsies were taken could 
be seen as small circular wounds (https://doi.org/10.1111/vco.12402).
can be toxic for dividing endothelial cells after pro-
longed exposure (Galbraith et al., 2001). In animals, it 
has been confirmed that dividing cells that are present 
in the gastrointestinal tract and lymphoid tissues, are 
affected when CA4P is administered at or above the 
maximum tolerated dose (Zweifel and Rustin, 2010).
In this case report, a fifteen-year-old dog with an 
inoperable PNST on the carpus that received CA4P 
treatment, is described. Special attention is given to 
the different methods that can be used to assess the 
treatment effect of such vascular disruptive agent and 
the clinical results of treatment with CA4P.
CASE REPORT
A fifteen-year-old, male, castrated American Staf-
fordshire terrier was presented with a large mass on 
the right carpal joint. In the past, a PNST had already 
been removed twice from the same location. On both 
occasions, it recurred after six months. The present 
mass had been growing slowly but consistently over 
the past year. Despite the extent of the tumor, the dog 
was not lame. 
On physical examination, no abnormalities were 
found apart from the presence of the mass. The tumor 
itself was solid with an ulcerative and reddish aspect, 
and the surrounding tissue was swollen (Figure 1A). 
Blood analysis did not reveal any abnormalities. Me-
tastasis was ruled out by thoracic radiographs and a 
complete ultrasound examination of the abdomen. 
Local excision, even if marginally, was not an op-
tion due to the size of the mass. Therefore, limb ampu-
A B
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tation with curative intent was advised but declined. 
The owner reported that the dog had arthrosis in both 
stifle joints. Furthermore, she firmly believed that a 
three-legged dog would be an unhappy dog, anyhow. 
Since PNSTs are not sensitive to chemotherapy, the 
owner was informed about an ongoing experimen-
tal clinical trial on the use of the vascular disrupting 
agent CA4P in dogs with solid neoplasia.
To obtain more information about the vasculariza-
tion of the tumor, B-mode, power-Doppler ultrasound 
(PDUS), contrast-enhanced ultrasound (CEUS) and 
biopsies were performed. A routine B-mode ultra-
sonography of the mass was performed and a linear 
transducer with a frequency of 4Hz was used. On B-
mode images, the tumor could be defined as a solid 
mass. The mass was scanned from a dorsal to palmar 
region and vasculature was prominent and clearly 
outspoken in de central part as well as at the periph-
ery of the tumor (Figure 2A). For the CEUS images, 
a linear transducer of 12-5 MHz was used, combined 
with a frame rate of 8 Hz. There was a large uptake of 
microbubbles throughout the septa of the tumor and 
the uptake went from the periphery to the central part 
of the tumor (Figure 3A). A biopsy of the mass was 
taken after all imaging was performed and before the 
treatment with CA4P was started. The protocol used 
for the sedation was an intravenous injection of both 
butorphanol (Dolorex®, 0.2 mg kg-1, MSD, Brus-
sels, Belgium) and dexmedetomidine (Dexdomitor®, 
0.005 mg kg-1, Orion Corporation, Espoo, Finland). 
After sedation and clipping, two six-mm-punch biop- 
sies were taken and sent for histopathologic exa-
mination. On the histopathological sections before 
treatment, hematoxylin and eosin (HE) staining con-
firmed the diagnosis of malignant PNST (Figure 4A). 
Additional staining with anti-von Willebrand factor 
(vWF) was performed  to identify vessels in the tissue 
sections (Figure 5A). Two anti-vWF stainings were 
made; on each, five fields of view were screened. The 
anti-vWF-stained slides demonstrated a multitude of 
viable endothelial cells.
The dog was treated intravenously with a single 
dose of 75 mg CA4P per m2 dissolved in 10 mL phos-
phate buffered saline (PBS), infused over a period of 
thirty minutes. A PDUS was performed during the 
infusion and 24 and 72 hours after CA4P-adminis-
tration. The PDUS images after treatment showed a 
significant decrease in vascularization compared to 
the pretreatment images (Figure 2B). Power-Doppler 
images show that the vascularity index (VI) was at its 
highest before injection with CA4P. After injection, 
the VI started to decrease and was low at 24 hours and 
at its lowest at 72 hours. The vascularization in the 
central part of the tumor was completely absent; how-
ever, in the periphery, a small amount of vasculariza-
tion remained. One day after treatment, CEUS was re-
peated. On CEUS images, the uptake of microbubble 
contrast in the central part of the PNST after treatment 
Figure 2 A. Power-Doppler ultrasound images of the tumor before treatment. Blood flow through the tumor is visual-
ized as yellow-red dots. Vascularization is prominent in both the central part of the tumor, as well as at the periphery. 
B. Power-Doppler ultrasound images of the tumor three days after CA4P treatment. There is minimal blood flow 
remaining. 
Figure 3 A. B-mode (right) and contrast-enhanced (left) image of the tumor before treatment. The microbubbles, 
shown in orange, are taken up by the vasculature present in the mass, with a higher uptake in the septa. There is also 
a diffuse uptake of contrast in a large part of the tumor. B. B-mode (right) and contrast-enhanced ultrasound (left) 
image of the tumor one day after treatment. The uptake of microbubble contrast is less in het central part of the tumor 
compared to the periphery; however, the mass can still be identified. 
B
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was distinctly less than before treatment (Figure 3B). 
Biopsies were repeated three days after treatment. On 
the HE-stained slides, the tumor cells displayed signs 
of karyorhexis (Figure 4B). In the posttreatment biop-
sies stained with anti-vWF, the endothelial cells were 
decreased in number from a mean of 0.21% before to 
a mean of 0.06% after treatment, indicating a reduc-
tion in viable endothelial cell density (Figure 5B). 
After treatment, the dog remained hospitalized for 
one week and physical examination was carried out 
daily. Special attention was given to potential general, 
cardiovascular and neurological side effects of CA4P 
treatment. The dog was clinically stable during hos-
pitalization but did experience side effects of CA4P, 
such as nausea, ataxia on the hind limbs and pain in 
the tumoral region. Maropitant citrate (Cerenia®, 
Zoetis, Belgium) was administered intravenously and 
nausea passed in two hours after treatment. For the 
tumoral pain, Methadon hydrochloride (Comfortan®, 
1 mg kg-1, Dechra, UK) was administered intrave-
nously every four to six hours. The pain disappeared 
within 96 hours after CA4P administration. The ataxia 
was self-limiting and disappeared one week and a half 
after CA4P administration. 
Three weeks after treatment, the tumoral mass was 
macroscopically decreased in size, and the overlying 
skin had a less irritated and less ulcerative aspect. 
Small circular wounds were indicative of the regions 
where biopsies had been taken (Figure 1B). 
The dog returned for further follow-up, weekly for 
one month, and then monthly for five months. Five 
months after the CA4P treatment, the remaining mass 
got infected. Because of the poor response to local 
and systemic treatment, the owner decided to have the 
dog euthanized. 
Figure 5 A. Immunohistochemical staining for endothelial cells before treatment. The endothelial cell nuclei are dark 
brown and the tumoral cells stain blue (anti-von Willebrand factor; Scale bar = 100 µm). B. Immunohistochemical 
staining for endothelial cells after treatment. There are no endothelial cell nuclei visible after treatment (anti-von Wille- 
brand factor; Scale bar = 100 µm).
Figure 4 A. Histopathological sections of the tumor before treatment. The tumoral cells are lying in sheets with no dif-
ferentiation between tumoral cells and fibrovascular stroma. The cells are spindloid with a basophilic nucleus (hema-
toxylin and eosin; scale bar = 100 µm). B. Histopathological sections of the tumor three days after treatment. Necrosis 
can be seen as a big region of eosinophilic amorphous material consisted of cellular and nuclear debris (hematoxylin 
and eosin; scale bar = 100 µm). 
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DISCUSSION 
Different options are available when treating a 
PNST. Local tumor control is the most important con-
sideration in the management of soft tissue sarcomas 
because of their locally aggressive behavior (Liptak 
and Forrest, 2013). As such, surgical resection is the 
main treatment for soft tissue sarcomas. Surgical re-
moval of the mass without adequate margins result in 
incomplete resection and a high risk of local tumoral 
recurrence (McKnight et al., 2000; Liptak and For-
rest, 2013). In a retrospective study in 51 dogs with 
a PNST, the overall prognosis after surgical manage-
ment alone has been shown to be guarded to poor 
(Brehm et al., 1995). Recurrence and/or development 
of metastases are associated with decreased survival 
rate (McKnight et al., 2000). Yet, in this case with a 
PNST at the level of the carpus in the absence of me-
tastasis, forelimb amputation most likely would have 
been curative. However, the owner declined such ag-
gressive surgery. 
Radiation therapy is often used when treating 
soft tissue sarcomas. It can be used along with sur-
gery with a curative intent, either preoperatively or 
postoperatively, or as a sole treatment for pain pal-
liation (Liptak and Forrest, 2013). Similar to other 
soft-tissue sarcomas, an excellent long-term survival 
rate may be achieved in some dogs with resection of a 
PNST followed by radiation (McKnight et al., 2000). 
Multimodal therapy with marginal surgical excision 
and postoperative radiation therapy may be limb spar-
ing and reduce patient morbidity (Liptak and Forrest, 
2013). The patient described in this case report was 
not eligible for radiation therapy. Even marginal sur-
gical resection of the tumor would have resulted in a 
large skin defect, comprising more than half of the 
leg’s circumference. Complications, such as impaired 
venous and/or lymphatic drainage and the slow heal-
ing after free skin grafting, would create a delay in 
the start of radiation therapy in an attempt to limit the 
risk of early and late side effects. Palliative radiation 
therapy was not considered in this case because it has 
an analgesic rather than a curative intent (Kubicek, 
2018); moreover, the tumor was not considered pain-
ful to the dog. 
The value of chemotherapy in dogs with soft tis-
sue sarcomas, including PNST, is not known (Liptak 
and Forrest, 2013). In the past, it was claimed that the 
most promising chemotherapy protocol was doxoru-
bicin (Ogilvie et al., 1989). In the treatment of hem-
angiosarcoma in dogs, no benefit of combining doxo-
rubicin with another chemotherapeutic agent could 
be demonstrated (Ogilvie et al., 1996). More recent 
studies on the efficacy of chemotherapy protocols are 
not available.
Although not yet FDA-approved as anticancer 
treatment in domestic animals, CA4P was considered 
an alternative treatment option in the dog described 
in this case report. Single IV CA4P treatment resulted 
in massive necrosis of the malignant PNST. In hu-
man patients, CA4P is already FDA-approved for the 
treatment of several types of cancer and there are pre-
liminary data suggesting that adding CA4P to exist-
ing chemotherapy protocols improves overall survival 
(Garon et al., 2010; Ng et al., 2012; Sosa et al., 2014). 
Also, the combination of CA4P with radiotherapy is 
well tolerated in most patients (Ng et al., 2012). Treat-
ment with CA4P can contribute to a longer survival 
time (Garon et al., 2010). Vascular disruptive agents 
such as CA4P target and destroy the established tu-
mor vessels. They should not be confused with anti-
angiogenic agents (AAA); the last interfere with the 
de novo synthesis of blood vessels, thus preventing 
the formation of tumor vasculature (Siemann et al., 
2005). The exact mechanism behind CA4P has not yet 
been completely unraveled, but the main action is the 
disruption of the cytoskeleton of the immature endo-
thelial cells (Siemann et al., 2005). Binding of CA4P 
leads to tubulin depolymerization, inhibiting further 
cell proliferation. Consequently, the immature tu-
moral vessels collapse, leading to tumor hypoxia and 
necrosis. Because VDAs such as CA4P only target the 
immature vessels, there is little to no effect on other 
types of vasculature (Siemann et al., 2005). 
In this case, the vascular shutdown effect of a 
single dose of IV CA4P was evaluated by monitoring 
the effect on the vascularization of the tumor by three 
different means. Histopathology, complemented with 
immunohistochemistry, is still considered the gold 
standard to assess the treatment effect of antivascular 
therapy (Gee et al., 2001). The posttreatment surgical 
biopsies showed clear evidence of vessel destruction 
and necrosis. Routine histology slides stained with HE 
revealed zones with necrotic cells, whereas immuno-
histochemistry staining with anti-vWF identified less 
endothelial cells. Obviously, US monitoring of the 
antivascular effect is a more attractive technique than 
serial biopsies in clinical patients because it is non-in-
vasive. On B-mode images after treatment, the central 
part of the tumor was more hypoechogenic than the 
periphery but more specific information could not be 
gained. Yet, US techniques, such as PDUS and CEUS, 
reveal information on tissue perfusion through small 
vessels and the capillary bed, respectively (Wilson 
et al., 2009). Before treatment, the blood flow in the 
PNST was prominent throughout the entire tumor 
and was obvious on both PDUS and CEUS images. 
On the posttreatment PDUS and CEUS images, there 
was a marked decrease in vascularization compared 
to before treatment. It should be noted that PDUS is 
extremely sensitive to motion, causing flash artifacts 
that should not be mistaken for blood flow (Rubin et 
al., 1994). CEUS is an imaging modality that is not 
yet available to many clinicians, but is considered a 
promising, sensitive tool to assess in vivo vasculariza-
tion (Zhang et al., 2017).
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CONCLUSION
Up to now, conventional treatment of PNSTs has 
consisted of surgery or palliative radiotherapy. Re-
search proves that VDAs significantly destroy the vas-
culature of tumoral tissue and lead to necrosis of the 
tumoral mass. The use of VDAs, such as CA4P, should 
therefore be further explored in novel combination 
therapies as alternative treatment options for solid tu-
mors whenever radiation therapy, surgical resection, 
and/or conventional chemotherapy are not an option. 
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